Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.
Maesaka K, Hikita H, Kai M, Tahata Y, Shirai K, Doi A, Murai K, Saito Y, Yamada R, Kodama T, Ohkawa K, Miyazaki M, Ishida H, Matsumoto K, Nozaki Y, Yakushijin T, Sakamori R, Tatsumi N, Iio S, Nawa T, Kakita N, Nakahara M, Hosui A, Usui T, Imanaka K, Doi Y, Sakakibara M, Yoshida Y, Tatsumi T, Takehara T.
Maesaka K, et al. Among authors: iio s.
J Gastroenterol Hepatol. 2025 Oct;40(10):2580-2590. doi: 10.1111/jgh.70068. Epub 2025 Sep 9.
J Gastroenterol Hepatol. 2025.
PMID: 40922653
Free PMC article.